ATE318133T1 - Verwendung von stearidonsäure zur herstellung eines arzneimittels für die behandlung oder vorbeugung von krebs - Google Patents

Verwendung von stearidonsäure zur herstellung eines arzneimittels für die behandlung oder vorbeugung von krebs

Info

Publication number
ATE318133T1
ATE318133T1 AT00961816T AT00961816T ATE318133T1 AT E318133 T1 ATE318133 T1 AT E318133T1 AT 00961816 T AT00961816 T AT 00961816T AT 00961816 T AT00961816 T AT 00961816T AT E318133 T1 ATE318133 T1 AT E318133T1
Authority
AT
Austria
Prior art keywords
cancer
prevention
treatment
production
acid
Prior art date
Application number
AT00961816T
Other languages
German (de)
English (en)
Inventor
Mark Obukowicz
Ayman Kabakibi
Susan Hummert
Lisa M Olsen
Julie Lindemann
Original Assignee
Monsanto Technology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monsanto Technology Llc filed Critical Monsanto Technology Llc
Application granted granted Critical
Publication of ATE318133T1 publication Critical patent/ATE318133T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AT00961816T 1999-09-10 2000-09-11 Verwendung von stearidonsäure zur herstellung eines arzneimittels für die behandlung oder vorbeugung von krebs ATE318133T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/393,790 US6340705B1 (en) 1999-09-10 1999-09-10 Use of α-linolenic acid metabolites for treatment or prevention of cancer

Publications (1)

Publication Number Publication Date
ATE318133T1 true ATE318133T1 (de) 2006-03-15

Family

ID=23556262

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00961816T ATE318133T1 (de) 1999-09-10 2000-09-11 Verwendung von stearidonsäure zur herstellung eines arzneimittels für die behandlung oder vorbeugung von krebs

Country Status (9)

Country Link
US (2) US6340705B1 (enExample)
EP (1) EP1237545B1 (enExample)
JP (1) JP2003508484A (enExample)
AT (1) ATE318133T1 (enExample)
AU (1) AU7371600A (enExample)
CA (1) CA2384502C (enExample)
DE (1) DE60026152T2 (enExample)
MX (1) MXPA02002681A (enExample)
WO (1) WO2001017517A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040037892A1 (en) * 2001-11-19 2004-02-26 Adrianne Bendich Dietary composition containing conjugated linoleic acid and calcium for improved health
AU2002309931A1 (en) * 2001-05-17 2002-11-25 Pilot Therapeutics, Inc. Method for enriching tissues in long chain polyunsaturated fatty acids
US6977271B1 (en) * 2001-08-30 2005-12-20 Health Research, Inc. Method for inhibition of angiogenesis and vasculogenesis
GB0311081D0 (en) * 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
CA2436650A1 (en) * 2003-08-06 2005-02-06 Naturia Inc. Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses
GB2422373B (en) 2003-08-18 2008-05-21 Btg Int Ltd Treatment of neurodegenerative conditions
CN102134230B (zh) * 2004-03-15 2019-06-28 武田药品工业株式会社 二肽基肽酶抑制剂
US20050266051A1 (en) * 2004-05-27 2005-12-01 The Procter & Gamble Company Pet food compositions and methods
US7456270B2 (en) * 2004-09-01 2008-11-25 Abbott Laboratories Δ6-desaturase genes and uses thereof
DE202004015931U1 (de) * 2004-10-13 2005-01-05 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Omega-3-Fettsäuren und Omega-6-Fettsäuren enthaltende Zusammensetzung
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
US8092839B2 (en) * 2004-12-13 2012-01-10 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer and other diseases
US8431165B2 (en) * 2004-12-13 2013-04-30 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer and other diseases
GB0504362D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
US7481870B2 (en) * 2006-04-18 2009-01-27 Oreck Holdings, Llc Electrode wire for an electrostatic precipitator
PL2026828T3 (pl) 2006-06-08 2015-11-30 Iams Europe B V Zastosowanie co najmniej jednego polifenolu do wspomagania zdrowia oczu
FR2904554B1 (fr) * 2006-08-04 2010-11-05 Zheng Xu Lipides moleculaires heterogenes cytotropes (lmhc), procede de preparation, et methodes de traitement de patients porteurs de cancers multiples
US20100010088A1 (en) * 2007-11-01 2010-01-14 Wake Forest University School Of Medicine Compositions and Methods for Prevention and Treatment of Mammalian Diseases
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
CN101903028B (zh) * 2007-12-19 2013-06-05 普罗米蒂克生物科学公司 与吉西他滨组合用于治疗胰腺癌的中等链长脂肪酸、盐类及三酸甘油酯
US20090197955A1 (en) * 2008-01-31 2009-08-06 Monsanto Company Methods of improving dha deposition and related function and/or development
US8060617B2 (en) * 2008-12-19 2011-11-15 Cisco Technology, Inc. Reserving network resources during scheduling of meeting event
US8372465B2 (en) * 2010-02-17 2013-02-12 Bunge Oils, Inc. Oil compositions of stearidonic acid
EP2425833A1 (de) * 2010-09-03 2012-03-07 Fresenius Kabi Deutschland GmbH Die intravenöse Applikation von Fischöl/DHA +EPA vor bzw. mit Beginn der Chemotherapie
WO2012141575A1 (en) * 2011-04-14 2012-10-18 N.V.Nutricia Combination of epa, dpa and/or dha with a chemotherapeutic agent
US10076550B2 (en) * 2014-06-25 2018-09-18 Council Of Scientific & Industrial Research Synergistic pharmaceutical composition for gastroinestinal disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
HU203660B (en) * 1987-04-23 1991-09-30 Biogal Gyogyszergyar Improved process for producing food-additive composition rich in omega-3-unsaturated fatty acids
CN1035925C (zh) * 1988-11-16 1997-09-24 许正 亲细胞非均质分子脂质的制备方法
EP0457950B1 (fr) * 1990-05-23 1993-10-20 Societe Des Produits Nestle S.A. Utilisation de l'acide stéaridonique pour le traitement des maladies inflammatoires
GB9012651D0 (en) * 1990-06-06 1990-07-25 Efamol Holdings Essential fatty acid treatment
EP0585058A1 (en) * 1992-08-25 1994-03-02 Scotia Holdings Plc Pharmaceutical compositions containing fatty acids and heparin
EP0585057A1 (en) * 1992-08-25 1994-03-02 Scotia Holdings Plc Lithium salts of fatty acids for the treatment of viral infections and cancer
CA2119000A1 (en) 1993-03-19 1994-09-20 David Frederick Horrobin Formulation for use in smokers
US5925669A (en) * 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
JPH0853351A (ja) * 1994-08-11 1996-02-27 Sagami Chem Res Center 酵素阻害剤、血管新生抑制剤、および癌転移抑制剤
KR970002037B1 (ko) * 1994-12-09 1997-02-21 농촌진흥청 들깨유로부터 α-리놀렌산(ALA)을 분리, 정제하는 방법
US5639787A (en) * 1995-02-28 1997-06-17 The Center For The Improvement Of Human Functioning Int'l, Inc. Therapeutic method for the treatment of cancer
US6077828A (en) 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
DK0843972T3 (da) 1996-11-20 2002-12-02 Nutricia Nv Næringsmiddelsammensætning, der indeholder fedtstoffer til behandling af stofskiftesygdomme
DE19757414A1 (de) * 1997-12-23 1999-07-01 Nutricia Nv Fettmischung

Also Published As

Publication number Publication date
WO2001017517A3 (en) 2002-07-11
DE60026152D1 (de) 2006-04-27
EP1237545B1 (en) 2006-02-22
JP2003508484A (ja) 2003-03-04
US20020010211A1 (en) 2002-01-24
CA2384502A1 (en) 2001-03-15
WO2001017517A2 (en) 2001-03-15
DE60026152T2 (de) 2006-11-16
CA2384502C (en) 2011-01-18
MXPA02002681A (es) 2003-10-14
EP1237545A2 (en) 2002-09-11
AU7371600A (en) 2001-04-10
US6340705B1 (en) 2002-01-22

Similar Documents

Publication Publication Date Title
ATE318133T1 (de) Verwendung von stearidonsäure zur herstellung eines arzneimittels für die behandlung oder vorbeugung von krebs
ATE214287T1 (de) Verwendung von relaxin zur herstellung eines arzneimittels für die behandlung kardiovaskulären krankeiten.
ATE427114T1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomíostase stírungen
ATE332702T1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
DE69636085D1 (de) Verwendung von gamma-Linolensäure oder Dihomogammalinolensäure zur Herstellung eines Medikaments zur Behandlung von Huntington's Chorea
ATE152910T1 (de) Verwendung von taxol zur herstellung eines arzneimittels zur behandlung von krebs
ATE523194T1 (de) Bis(thiohydrazidamide) in kombination mit taxol für die behandlung von krebs
ATE231885T1 (de) Verwendung von komplement-inhibitoren zur herstellung eines arzneimittels zur prophylaxe und therapie von entzündlichen darm- und hauterkrankungen sowie purpura
ATE406371T1 (de) Wirkstoffe für die verminderung von amyloid precursor protein und die behandlung von schwachsinn, und deren verfahren der verwendung
ATE274916T1 (de) Verwendung von substanzen mit oxytocinwirkung zur herstellung eines arzneimittels zur behandlung affektiver schmerzsyndrome
EP1098642A4 (en) METHODS OF TREATING MODULATED CONDITIONS WITH LACTOSYLCERAMIDE
ZA202210079B (en) Compositions and methods for treating or preventing inflammatory diseases including diabetes mellitus 10 type i and type ii and thyroid diseases
HUT68589A (en) The cyclodextrin cluster complexes of taxol, taxotere, or taxus, process for their production, and use of them
DE69717849D1 (de) Lektinzusammenstellungen und deren verwendung
ATE293976T1 (de) Verbindungen enthaltend s-tofisopam sowie verwendung dieser verbindungen zur herstellung eines medikamentes zur behandlung oder prophylaxe von krämpfen und anfällen
ATE274349T1 (de) Verwendung von fruktan zur herstellung eines arzneimittels zur vorbeugung und behandlung von dickdarmkrebs
DE69916632D1 (de) Verwendung von zimtsäurederivaten zur herstellung eines medikamentes zur vorbeugung oder behandlung von erkrankungen die durch einen hohen blutfettspiegel bedingt sind
DE69921662D1 (de) Verwendung von gingko biloba extrakten zur herstellung eines arzneimittels zur behandlung der amyotrophen lateralsklerose
DE59914712D1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
ATE272404T1 (de) Verwendung von taurolidine zur herstellung eines arzneimittels zur behandlung von leukämien
ATE289816T1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
DE60115054D1 (de) Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs
DE60027127D1 (de) Verwendung von Polyaminosäurederivaten zur Behandlung von Seborrhoe und verwandten Hautstörungen
HU9201799D0 (en) New 2-amino-5-ciano-1,4-dihydropiridine-derivatives, process for their use and their use as medicaments
ATE286402T1 (de) Verwendung von morinda citrifolia zur behandlung von tinnitus

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties